FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947302571> ?p ?o ?g. }

• W2947302571 endingPage "3490" @default.
• W2947302571 startingPage "3472" @default.
• W2947302571 abstract "Melanoma is a deadly form of malignancy and according to the World Health Organization 132,000 new cases of melanoma are diagnosed worldwide each year. Surgical resection and chemo/drug treatments opted for early and late stage of melanoma respectively, however detrimental post surgical and chemotherapy consequences are inevitable. Noticeably melanoma drug treatments are associated with liver injuries such as hepatitis and cholestasis which are very common. Alleviation of these clinical manifestations with better treatment options would enhance prognosis status and patients survival. Natural products which induce cytotoxicity with minimum side effects are of interest to achieve high therapeutic efficiency. In this study we investigated anti-melanoma and hepatoprotective activities of frankincense essential oil (FEO) in both in vitro and in vivo models. Pretreatment with FEO induce a significant (p < 0.05) dose-dependent reduction in the cell viability of mouse (B16-F10) and human melanoma (FM94) but not in the normal human epithelial melanocytes (HNEM). Immunoblot analysis showed that FEO induces down regulation of Bcl-2 and up regulation of BAX in B16-F10 cells whereas in FM94 cells FEO induced dose-dependent cleavage of caspase 3, caspase 9 and PARP. Furthermore, FEO (10 μg/ml) treatment down regulated MCL1 in a time-dependent manner in FM94 cells. In vivo toxicity analysis reveals that weekly single dose of FEO (1200 mg/kg body weight) did not elicit detrimental effect on body weight during four weeks of experimental period. Histology of tissue sections also indicated that there were no observable histopathologic differences in the brain, heart, liver, and kidney compare to control groups. FEO (300 and 600 mg/kg body weight) treatments significantly reduced the tumor burden in C57BL/6 mice melanoma model. Acetaminophen (750 mg/kg body weight) was used to induce hepatic injury in Swiss albino mice. Pre treatment with FEO (250 and 500 mg/kg body weight) for seven days retained hematology (complete blood count), biochemical parameters (AST, ALT, ALK, total bilirubin, total protein, glucose, albumin/globulin ratio, cholesterol and triglyceride), and the level of phase I and II drug metabolizing enzymes (cytochrome P450, cytochromeb5, glutathione-S-transferase) which were obstructed by the administration of acetaminophen. Further liver histology showed that FEO treatments reversed the damages (central vein dilation, hemorrhage, and nuclei condensation) caused by acetaminophen. In conclusion, FEO elicited marked anti-melanoma in both in vitro and in vivo with a significant heptoprotection." @default.
• W2947302571 created "2019-06-07" @default.
• W2947302571 creator A5002137602 @default.
• W2947302571 creator A5011047002 @default.
• W2947302571 creator A5017376934 @default.
• W2947302571 creator A5048089786 @default.
• W2947302571 creator A5055905860 @default.
• W2947302571 creator A5058240016 @default.
• W2947302571 creator A5065351671 @default.
• W2947302571 creator A5072536978 @default.
• W2947302571 creator A5077952358 @default.
• W2947302571 creator A5079513373 @default.
• W2947302571 creator A5087192033 @default.
• W2947302571 creator A5090257452 @default.
• W2947302571 date "2019-05-28" @default.
• W2947302571 modified "2023-10-15" @default.
• W2947302571 title "Frankincense essential oil suppresses melanoma cancer through down regulation of Bcl-2/Bax cascade signaling and ameliorates heptotoxicity via phase I and II drug metabolizing enzymes" @default.
• W2947302571 cites W1137404219 @default.
• W2947302571 cites W1480948328 @default.
• W2947302571 cites W1498584605 @default.
• W2947302571 cites W1546398239 @default.
• W2947302571 cites W1581414347 @default.
• W2947302571 cites W1582805634 @default.
• W2947302571 cites W1597813032 @default.
• W2947302571 cites W1748998307 @default.
• W2947302571 cites W1826271789 @default.
• W2947302571 cites W1936122156 @default.
• W2947302571 cites W1964625584 @default.
• W2947302571 cites W1970206154 @default.
• W2947302571 cites W1971078959 @default.
• W2947302571 cites W1972011439 @default.
• W2947302571 cites W1975517560 @default.
• W2947302571 cites W1978288476 @default.
• W2947302571 cites W1995631390 @default.
• W2947302571 cites W1999994416 @default.
• W2947302571 cites W2000003883 @default.
• W2947302571 cites W2001758437 @default.
• W2947302571 cites W2007195740 @default.
• W2947302571 cites W2014620175 @default.
• W2947302571 cites W2014647470 @default.
• W2947302571 cites W2021977295 @default.
• W2947302571 cites W2027299002 @default.
• W2947302571 cites W2028996724 @default.
• W2947302571 cites W2032758907 @default.
• W2947302571 cites W2033408660 @default.
• W2947302571 cites W2034284608 @default.
• W2947302571 cites W2034372828 @default.
• W2947302571 cites W2036411709 @default.
• W2947302571 cites W2043449872 @default.
• W2947302571 cites W2045410662 @default.
• W2947302571 cites W2049715428 @default.
• W2947302571 cites W2052214665 @default.
• W2947302571 cites W2052781279 @default.
• W2947302571 cites W2068368560 @default.
• W2947302571 cites W2069228445 @default.
• W2947302571 cites W2074305443 @default.
• W2947302571 cites W2086851270 @default.
• W2947302571 cites W2091205807 @default.
• W2947302571 cites W2102123085 @default.
• W2947302571 cites W2111251544 @default.
• W2947302571 cites W2111557145 @default.
• W2947302571 cites W2114060459 @default.
• W2947302571 cites W2116748450 @default.
• W2947302571 cites W2123692379 @default.
• W2947302571 cites W2125963106 @default.
• W2947302571 cites W2127505226 @default.
• W2947302571 cites W2130919666 @default.
• W2947302571 cites W2139410513 @default.
• W2947302571 cites W2139870153 @default.
• W2947302571 cites W2140279988 @default.
• W2947302571 cites W2140355798 @default.
• W2947302571 cites W2140955159 @default.
• W2947302571 cites W2144163410 @default.
• W2947302571 cites W2145050940 @default.
• W2947302571 cites W2164959460 @default.
• W2947302571 cites W2172188407 @default.
• W2947302571 cites W2205394433 @default.
• W2947302571 cites W2210852924 @default.
• W2947302571 cites W2324605323 @default.
• W2947302571 cites W2336608924 @default.
• W2947302571 cites W2341518158 @default.
• W2947302571 cites W2462606993 @default.
• W2947302571 cites W2550314149 @default.
• W2947302571 cites W2583629504 @default.
• W2947302571 cites W2765739536 @default.
• W2947302571 cites W2765827083 @default.
• W2947302571 cites W2774422313 @default.
• W2947302571 cites W2782036233 @default.
• W2947302571 cites W2804996603 @default.
• W2947302571 cites W2952688862 @default.
• W2947302571 cites W4211139904 @default.
• W2947302571 cites W4231135359 @default.
• W2947302571 cites W4235551585 @default.
• W2947302571 cites W2130090719 @default.
• W2947302571 doi "https://doi.org/10.18632/oncotarget.26930" @default.
• W2947302571 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7289534" @default.
• W2947302571 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32577169" @default.
• W2947302571 hasPublicationYear "2019" @default.

• next